Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal MelanomaC. Mignard, P. Joly, F. Aubin et al.|Journal of Oncology|2018Cited by 82
Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanomaC. Mignard, P. Joly, A. Deschamps-Huvier et al.|Annals of Oncology|2018Cited by 13
Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenibPhilippe Saïag, Caroline Dutriaux, Caroline Robert et al.|European Journal of Cancer|2021Cited by 13
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastasesCaroline Dutriaux, Philippe Saïag, Jean‐Jacques Grob et al.|European Journal of Cancer|2022Cited by 13
Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial.Laurent Mortier, Émilie Le Rhun, Philippe Jamme et al.|Journal of Clinical Oncology|2018Cited by 4